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Since 1980, advanced lung carcinomas were treated with palliative laser therapy for the
purpose of opening the endobronchial stenosis and obstruction by either photodynamic
therapy (PDT) or Nd-YAG laser treatment at Tokyo Medical University. A total of 258
lesions were treated, 81 byPDT and 177 byNd-YAG laser treatment.PDT achieved effective
results in 61 (75%) of81 lesions. In theNd-YAG laser group, 143(81%) of177 lesions showed
effective results. When the tumor was located in the trachea or main bronchi, effective results
were obtained in73% (19 of26) ofcases treatedbyPDT and in93% ofcases (64 of69) treated
by Nd-YAG laser. However, in cases in which the tumor was located in lobar or segmental
bronchi, the tumor response was effective in76% (42 of55) ofPDT-treated patients and73%
(79 of 108) of Nd-YAG laser-treated patients. With a mortality rate of 0%, the greatest
advantage of PDT over Nd-YAG treatment was safety. Considering complications, PDT
seems to be useful for obstruction of lobar and segmental bronchus. Nevertheless, when
deciding among alternative therapies, physicians treating patients with advanced lung
carcinoma should give careful consideration to the benefit and complications of both laser
therapies and decide the most suitable modality.
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INTRODUCTION
Endoscopic surgery using laser is recognized as an
effective modality for endobronchial carcinoma.
Recently, however, attention has increasingly been
focused on photodynamic therapy (PDT) with
photosensitizer, i.e., Photofrin(R). The Japanese
government approved the use of this modality
for early stage lung carcinoma in October 1995,
and reimbursement through the National Health
Insurance began in April 1996. The result of PDT
for early stage lung carcinoma at our institution
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showed an excellent complete remission rate
(83.7%). Therefore, PDT is a good indication for
central type early stage lung carcinoma.
However, little can be done in cases of advanced
stage lung carcinoma. Only 12% ofstage III patients
survive for 2 years regardless oftherapy [1,2]. Trans-
bronchial resection using theneodymium yttrium-
aluminum-garnet (Nd-YAG) laser has become well
accepted after the initial reports of its efficacy were
published. Transmitted through optical fibers, the
Nd-YAG laser provides excellent vaporization, low
absorption by hemoglobin, and good tissue pene-
tration 5-10mm from the focal point with high-
energy output. Good results were reported in cases
of symptomatic endobronchial tumor obstruction
treated with theNd-YAG laser [3]. The drawback of
this laser, however, is its nonspecificity. The Nd-
YAG laser produces a beam that not only vaporizes
or coagulates tumor tissue but that may also harm
normal bronchial tissues and thus lead to severe
bleeding or perforation of the bronchial wall.
Treatment with the Nd-YAG laser may improve
ventilation of patients with endobronchial tumors,
but only partial removal of the tumor should be
attempted using this method [4]. With PDT, the
endobronchial tumor, if small enough, can be
eliminated completely with no fear of complica-
tions. In patients in the United States and Europe
with lung carcinoma or endobronchial metastatic
lesions, the primary use ofPDT is for palliation of
endobronchial obstruction in patients who have
intrinsic lesions ofthe bronchus that cause partial or
complete obstruction [5]. In this paper, we have
discussed the effectiveness of PDT and Nd-YAG
laser treatments performed at our institution for
obstructed lung carcinoma.
PATIENTS AND METHODS
Patients
Since 1980, a total of 258 lesions were performed
through palliative laser therapy for the purpose of
opening the endobronchial stenosis and obstruction
by either PDT or Nd-YAG laser therapy at Tokyo
Medical University. Among them, PDT group was
31% (81/258), and Nd-YAG laser group was 69%
(177/258). The population ofPDT group consisted
of 72 male and 6 female in a total of 78 cases (81
lesions). The mean age was 65.0 years (ranging
from 41 to 84 years). According to the histology,
65 lesions were those ofsquamous cell carcinoma, 9
lesions inadenocarcinoma, 4 in small cellcarcinoma,
large cell carcinoma in 2 cases and in metastatic
lung tumor. The majority ofhistology was found in
squamous cell carcinoma, which occupied 80% of
PDT group.
Treatment Methods
Both laser treatments were performed by flexible
bronchofiberscopy under local anesthesia using4%
xylocaine. Nd-YAG laser system (Olympus, model
MYL-2) was used for laser vaporization. The wave-
length at 1,064nm was irradiated to the lesions and
the energy was from 20 to 40W. Non-contact fiber
was used and laser irradiation time was 1.0 to 2.0 s
repeatedly.
Tumor selective photosensitizer was necessary
to perform PDT. As a photosensitizer, hemato-
porphyrin derivative (HpD; Photofrin Medical Inc.,
Cheektogawa, NY) or Photofrin
(R) (QOL Inc.,
Vancouver, Canada) was used for PDT. The photo-
sensitizer was administered at 2.0mg/kg intrave-
nously and at 48 or 72 h after administration, laser
irradiation at 630nm which is the longest absorp-
tion band ofHpD and Photofrin
(R) was performed.
Since 1980-1985, argon dye laser system (Spectra
Physics), and thereafter excimer dye laser system
developed by cooperation of Tokyo Medical
University and Hamamatsu Photonics Inc. were
employed for PDT. The laser beam was transmitted
via a 400 nm-quartz fiber inserted in the instrumen-
tation channel ofa fiberoptic bronchoscope. The tip
of the quartz fiber was maintained at a distance of
1-2cm from the lesion for surface irradiation or the
fiber was inserted into the obstructed tumor (inter-
stitial irradiation). Depends on tumor size, com-
binations of both irradiation methods were used.
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Evaluation of Treatment Effects
All cases were evaluated one month later, except
emergent cases for Nd-YAG laser treatment. Cases
in which tumor size or the degree of bronchial
obstruction was reduced by more than 50% were
classified as effective in terms of tumor response.
Ineffective cases were those in which tumor size or
the degree of obstruction was reduced by less than
50% [5]. Emergent cases performed Nd-YAG laser
for the purpose of immediate relief from severe
dyspnea were also classified as effective ifthe tumor
was not reduced bymore than 50%.We investigated
the number ofbronchoscopic application and com-
plications to compare the benefits of the both
modalities. Furthermore, we also compared the
data of PaO2 and performance status (PS) before
and after PDT to estimate PDT efficacy.
RESULTS
A total of 258 lesions were treated, 81 by PDT and
177 by Nd-YAG laser treatment. PDT achieved
effective results in 61 (75%) of 81 lesions. In the
Nd-YAG laser group, 143 (81%) of 177 showed
effective results. Bronchoscopical findings of PDT
and Nd-YAG laser before and after treatment were
shown in Figs. and 2. In this study, effective tumor
response depending on tumor location was also
examined. Location ofthe lesions and the efficacy of
laser treatment were shown in Table I. Four lesions
(5%) in trachea, 22 lesions (27%) in main bronchus,
36 lesions (44%) in lobar bronchus and 19 lesions
(24%) in segmental bronchus were treated by PDT.
On the other hand, 69 lesions (39%) in trachea and
main bronchus and 108 lesions (61%) in lobar and
segmental bronchus were treated byNd-YAG laser.
When the tumor was located in the trachea or main
bronchi, effective results were obtained in 73% (19
of26) ofcases treated byPDT and in 93% (64 of 69)
treated by Nd-YAG laser. However, in cases in
which the tumor was located in lobar or segmental
bronchi, the tumor response was effective in 76%
(42 of 55) of PDT-treated patients and 73% (79 of
108) ofNd-YAG laser-treated patients.
Complications of PDT and Nd-YAG laser
therapy were shown in Table II. No fatal complica-
tions occurred in any of the PDT treated patients,
whereas 91% (71 of 81) of patients developed slight
skin photosensitivity, although no patient required
treatment. Other complications of PDT were
pneumonia in 4 cases (6%), slight fever in 2 cases
Pre-Treatment Post-Treatment
FIGURE PDT using Photofrin
(R) and excimer dye laser was performed for 90% obstruction of left upper bronchus. Excimer
of Photofrin intravenous injection. The laser energy was adjusted to dye laser irradiation was performed at 48 h after 2.0mg/kg
(R)
4 mJ/pulse with 30 Hz of frequency and the total laser energy was 400 J. Opening of bronchial obstruction was obtained at 2 days
after PDT by bronchial toileting.164 K. FURUKAWA et al.
Pre-Treatment Post-Treatment
FIGURE 2 Nd-YAG laser vaporization was performed for the complete obstruction of right main bronchus. Total laser energy
of Nd-YAG laser was 12,500 J at 30W. Severe dyspnea was improved dramatically after opening the bronchial lumen.
TABLE Location of lesions and efficacy of laser treatment
Location PDT Nd-YAG
Trachea and main bronchus 73% (19/26)
Lobar and segmenta bronchus 76% (42/55)
Total 75% (61/81)
93% (64/69)
73% (79/108)
81% (143/177)
TABLE II Complications of laser treatment
Treatment Complication Mortality
PDT Photosensitivity 71 (91%)
Pneumonia 4 (6%)
Slight fever 2 (3%)
Nd-YAG Pneumonia 12 (7%)
Massive bleeding 10 (6%)
Arrhythmia 8 (5%
Perforation 4 (3%)
0(0%)
3(1.7%)
(3%), which were not directly related with PDT
procedure, but the percentage were very low. Severe
complications, including massive bleeding in 10
patients (6%) and bronchial perforation in 4 cases
(3%) occurred in the Nd-YAG treated group. As a
result ofthese complications, 3 patients (1.3%) died.
The mortality of laser therapy was 0% in PDT,
1.7% in Nd-YAG treatment.
The numbers of bronchoscopic application per-
formed for laser treatment and bronchial toileting
were different between the 2 groups (Table Ill). In
TABLE III Numbers of bronchoscopic application
Treatment No. of Tx. % of cases % of toileting
PDT 0 0
91 5
>2 9 95
Nd-YAG 0 35
31 55
>2 69 10
TABLE IV Evaluation of improvement by PDT
Pre-treatment Post-treatment
PaO2 (mmHg) 66+ 21 82 + 14
Performance status 1.8 + 0.5 0.8 -+-0.4
the PDT group, laser irradiation was usually only
once (91%), but bronchial toiletings afterPDT were
necessary more than twice (95%). On the contrary,
laser irradiation of Nd-YAG laser was necessary
more than twice (69%), but less than once (90%)
bronchoscopy was sufficient for toileting.
To evaluate quality of life (QOL) of the patients
after PDT, we compared the data of PaO2 and
performance status (PS) before and after PDT to
estimate PDT efficacy in 15 cases (Table IV). The
averages of PaO2 and PS were 66mmHg and 1.8.
After PDT, the averages increased to 82mmHg
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DISCUSSION
Endoscopic surgery using Nd-YAG laser and PDT
has now achieved a status as effective therapeutic
modality for endobronchial carcinoma. Especially
increasing attention has been focused onPDT using
Photofrin
(R) and other photosensitizers. PDT for
early stage lung carcinoma obtained government
approval in October 1994 and finally obtained
Japanese National Health Insurance reimburse-
ment status in April 1996.
Since 1980, 248 patients (296 lesions) with central
type lung carcinomas included early stage and
advanced carcinoma have been treated in our
institute. Overall complete remission was obtained
in 42.5% of the 125 lesions, partial remission in
56.8% and no remission was obtained in 1.0%.
Especially in early stage lung carcinoma as a
curative purpose, CR was obtained in 107 (84.9%)
out of 126 cases and 61 cases were disease free at 2 to
200 months. So far in Japan, PDT is approved
only for early stage lung carcinoma because of
the excellent result. However, PDT has good
indications for not only early stage lung carcinoma,
but also preoperative laser irradiation for the
purposes of increasing operability and reducing
the extent ofresection area and opening the bronchi
for advanced lesions.
In this paper, we have demonstrated the efficacy
ofPDT andNd-YAG laser treatment for obstructed
lung carcinoma. Overall effective opening of
bronchi was achieved in 61 out of 81 lesions (75%)
for thePDT treated group, as opposed to 143 of 177
(81%) for the Nd-YAG laser-treated group. When
the tumor was located in the trachea or main
bronchi, effective results were obtained in 73% (19
of26) ofcases treated byPDT and in 93% (64 of 69)
treated by Nd-YAG laser. However, in cases in
which the tumor was located in lobar or segmental
bronchi, the tumor response was effective in 76%
(42 of 55) ofPDT treated patients and 73% (79 of
108) ofNd-YAG laser-treated patients. Therefore,
Nd-YAG laser treatment was useful for obstruction
of large bronchus (trachea and main bronchus), on
the other hand, the similar results were obtained
by PDT for obstruction of lobar and segmental
bronchus.
The procedures also differed in that the laser used
in PDT could be inserted safely into the tumor for
treatment without perforation or harm to adjacent
vessels. With the Nd-YAG laser, however, bron-
chial wall perforation or massive hemorrhaging
resulting from the blood vessel injury sometimes
occurred [6]. This study shows that in the bronchial
wall, tumor necrosis is not induced as effectively by
Nd-YAG laser treatment as it is by PDT. This is
true, especially in the smaller bronchi, because of
the lesser margin for error with the Nd-YAG laser
before entering the vessel. Nd-YAG treatment in
distal bronchi is extremely difficult and dangerous.
Hemorrhage from pulmonary vessels was one ofthe
major complications of using the Nd-YAG laser,
but hemorrhaging did not occur with PDT. Similar
to our experience, McCaughan et al. had reported
no intraoperative death or cases of intraoperative
bleeding or smoke with 118 PDT cases [7]. With a
mortality rate of0%, the greatest advantage ofPDT
over Nd-YAG treatment is safety. Considering the
complication, PDT seems to be useful for obstruc-
tion of lobar and segmental bronchus.
Toilet bronchoscopy after laser therapy was
different in the PDT treated group and the Nd-
YAG treated group. Clean up after PDT involved
the simple removal of gelatinous or fibrinous plugs
from the bronchus in large pieces, but frequent
bronchoscopy is stressful for some patients. On
the other hand, Nd-YAG treatment required time-
consuming piecemeal forceps removal of charred
and coagulated tissue resulting from the treatment,
but in most cases, the toileting bronchoscopy was
sufficient for once.
Since Balchum and Doiron had demonstrated the
good result, objective response rate; 98.6% (71/72)
of PDT for obstructed endobronchial carcinoma,
many investigators has studied the utility of PDT
for advanced lung carcinoma [5]. McCaughan et al.
had demonstrated the effects on arterial blood gas
levels after PDT (31 cases) and Nd-YAG laser (86
cases) treatment for advanced endobronchial malig-
nancies [8]. A strong, inverse linear relationships166 K. FURUKAWA et al.
was found in PaO2 and its initial level and between
PaCO2 and pH changes. They concluded that PDT
is no more harmful for acid-base metabolism and
respiratory functions than Nd-YAG laser tumor
ablation. Our data also showed the improvement of
PaO2 afterPDT. Lam et al. analyzed the response of
24 patients with obstructed bronchial tumors to
PDT [9]. PDT was found to be most effective when
the tumor was polipoid appearance, with little or no
submucosal invasion or peribronchial extension.
Patientswho had 50% ormore ofthe endobronchial
obstruction due to mucosal tumor had no evidence
of local tumor recurrence for a median interval of
22 weeks after PDT. The advantages and disadvan-
tages of PDT compared with the Nd-YAG laser
treatment were summarized by McCaughan et al.
[3]. The disadvantages ofPDT are: (a) photosensi-
tizer injection, from which skin photosensitivity
may result, (b) the required waiting period between
injection and treatment, and (c) the need to perform
frequent toilet bronchoscopy. The advantages of
PDT treatment are three fold: (a) the technical ease
allowed by its safety, thus allowing little chance
of perforation and little risk of intraoperative
hemorrhaging, (b) no endobronchial smoke, and
(c) freedom to insert the fiber blindly into tissue.
Although the advantages of PDT for treatment
of advanced obstructing bronchial malignancy are
emphasized, the first choice for patients with severe
respiratory distress is immediate Nd-YAG laser
therapy, because PDT requires a 2 to 3 day waiting
period for selective retention of photosensitizer
before laser irradiation. After laser irradiation,
photodynamic reaction also may cause severe
obstruction of bronchi because of mucosal edema
and necrotic tissue. Furthermore, patients treated
withPDT may be ambulatory, but because they are
instructed to avoid direct sunlight, their activity is
severely limited for at least 2 weeks of their short
remaining life span. Sutedja et al. had reported a
pilot study ofPDT for 26 cases of inoperable non-
small cell lung carcinoma, and concluded that the
clinical benefit ofPDT in advanced cases was small
[10]. In these days, second generation photosensi-
tizers for example Npe6 and m-THPC which are
able to excite by longer wavelength than Photofrin
(R)
has been developed [11,12], so deeper tissue pene-
tration and photodynamic effect are expectable. A
randomized trial seems to be necessary to determine
whether PDT or Nd-YAG laser treatment is more
effective in relieving endobronchial obstruction.
Nevertheless, when deciding among alternative
therapies, physicians treating patients with
advanced lung carcinoma should give careful con-
sideration to these problems and decide on the
most suitable modality.
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